Revista Peruana de Medicina Experimental y Salud Pública (Dec 2015)

Allelic variants of the cyp2d6: *4, *6 and *10 in a sample of resident from the Aragua state, Venezuela

  • Carlos Flores-Angulo,
  • Cecilia Villegas,
  • Yuselin Mora,
  • José Antonio Martínez,
  • Teresa Oropeza,
  • Nancy Moreno

DOI
https://doi.org/10.17843/rpmesp.2015.324.1767
Journal volume & issue
Vol. 32, no. 4
pp. 746 – 751

Abstract

Read online

The aim of this study was to determine the CYP2D6: * 4, * 6 and * 10 gene variants frequency and to predict the metabolizer phenotype in a sample of 145 unrelated apparently healthy individuals residing in the state of Aragua, Venezuela. Genotypes were determined by Polymerase chain reaction assays followed by restriction endonucleases digestion. The metabolizer phenotype prediction was made based on the activity score system. The frequencies of CYP2D6 * 4, * 6 and * 10 allelic variants were 14.5%, 0.3% and 1%. A significant percentage of individuals were categorized as heterozygote-extensive/intermediate (23.5%) and poor metabolizers (4.1%), this information has potential clinical impact, because the CYP2D6 protein is involved in the metabolism of drugs frequently prescribed as: carvedilol, captopril, chloroquine, codeine, fluoxetine, fluvastatin, haloperidol, idarubicin, indinavir, imatinib, loperamide, nifedipine, ondansetron and tamoxifen.

Keywords